Aridis Pharmaceuticals (ARDS) to Release Quarterly Earnings on Wednesday

Aridis Pharmaceuticals (NASDAQ:ARDS) is expected to be releasing its resultson Wednesday, August 19th. Analysts expect the company to post earnings of ($0.5960) per share and revenue of $0.2670 million for the quarter.

Aridis Pharmaceuticals Price Performance

NASDAQ:ARDS opened at $0.00 on Wednesday. Aridis Pharmaceuticals has a 1 year low of $0.00 and a 1 year high of $0.05. The stock has a market capitalization of $5,332.10, a price-to-earnings ratio of 0.00 and a beta of 49.66.

About Aridis Pharmaceuticals

Aridis Pharmaceuticals is a San Diego–based clinical-stage biotechnology company dedicated to developing immunotherapeutic products for the prevention and treatment of life-threatening bacterial and fungal infections. The company’s technology platform leverages monoclonal antibodies and inhaled antifungal formulations to address antibiotic-resistant respiratory pathogens and emerging inhalational threats. Aridis’ research focuses on targeting key virulence factors in organisms such as Pseudomonas aeruginosa and Staphylococcus aureus, with the aim of delivering novel therapeutic approaches for hospital-acquired and ventilator-associated pneumonias, catheter-related bloodstream infections and deep fungal infections of the lung.

Among the company’s pipeline candidates, AR-310 is a first-in-class inhaled monoclonal antibody against Pseudomonas aeruginosa, designed for both prophylactic and therapeutic use in patients with cystic fibrosis and those at high risk of ventilator-associated pneumonia.